US stocks rose on Monday, with fresh records for the Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) in sight as Wall Street ...

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug ...

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...

Sarepta stock took another dive Monday after the biotech company refused the FDA's request to voluntarily stop all shipments ...

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

Investing.com -- Sarepta Therapeutics Inc (NASDAQ: SRPT) stock tumbled 10% following the announcement that the U.S. Food and Drug Administration has placed a clinical hold on the company’s ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Sarepta Therapeutics faces challenges as the FDA halts gene therapy trials for LGMD and revokes AAVrh74 platform designation.

U.S. stock futures rise as investors brace for a high-stakes week packed with Tesla and Alphabet earnings and growing anxiety ...

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...